Officials cite forged papers, exec inaction in fake drug-Shanghai Daily

Officials cite forged papers, exec inaction in fake drug

Source Xinhua | May 24, 2006, Wednesday |

Print Edition

MORE details have emerged about the circumstances surrounding production of a fake drug that killed nine people in south China's Guangdong Province.

Authorities are reporting that chemical dealer Wang Guiping at the center of the scandal forged licenses, including his business license, drug registration and manufacturing licenses, to sell products to pharmaceutical companies.

Officials allege that Wang sold one ton of the industrial compound diglycol, claiming it was "propylene glycol," in the name of the Taixing General Chemical Plant in the eastern Jiangsu Province to a pharmaceutical company in Heilongjiang Province.

He made a 7,500-yuan (US$937.50) profit on the 14,500-yuan price, Jiangsu police and the provincial drug administration said.

The buyer, Qiqihar No. 2 Pharmaceutical Co Ltd, produced Armillarisin A with the industrial chemical, resulting in the deaths of nine people who used the drug in the southern Guangdong Province.

Armillarisin A is mainly administered as an injection to treat acute or chronic cholecystitis and chronic and atrophic gastritis.

However, the Qiqihar company's products caused pain in the alimentary canal and stomach, as well as kidney, liver and nerve damage, said Liao Xinbo, vice director of the Guangdong Provincial Department of Health.

Jiangsu police and drug administration officials said they also found Taixing General Chemical Plant had offered Wang its invoices and allowed him to do business in its name on condition of a 1-percent return on the invoices.

However, Wang continued to trade in the name of Taixing General Chemical Plant even after the plant ended its allegedly illegal partnership with him in July 2005.

Wang, 40, has been arrested by Jiangsu police. Cao Yongwen, director of the Qiqihar Municipal Food and Drug Administration, said the Qiqihar pharmaceutical company never identified the chemical as fake.

The company failed to test the so-called "propylene glycol" as required under State Drug Administration regulations before buying the chemical, nor did it cross-check the licenses provided by Wang Guiping, Cao said.

The company's analysts realized the material was substandard, but the plant still put it into production with consent of company executives, said a staff member who wanted to be identified only as Wang.

About Us
|
Terms of Use
|
RSS
|
Privacy Policy
|
Contact Us
|
Shanghai Call Center: 962288
|
Tip-off hotline: 52920043

沪ICP证：沪ICP备05050403号-1
|
互联网新闻信息服务许可证：31120180004
|
网络视听许可证：0909346
|
广播电视节目制作许可证：沪字第354号
|
增值电信业务经营许可证：沪B2-20120012

Officials cite forged papers, exec inaction in fake drug

Email this to your friend